Search

Finally, the proportion of patients documented twice with the highest antibody level at SpV2 and SpV2+/SpV3 was similar between V3- and V3+ patients (50% vs. 60%, I P i = 0-55). Vaccine, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA, coronavirus disease 2019 (COVID-19), allogeneic haematopoietic stem cell transplantation, BNT162b2, third dose Keywords: coronavirus disease 2019 (COVID-19); vaccine; allogeneic haematopoietic stem cell transplantation; BNT162b2; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA; third dose EN coronavirus disease 2019 (COVID-19) vaccine allogeneic haematopoietic stem cell transplantation BNT162b2 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA third dose e38 e40 3 02/28/22 20220301 NES 220301 The efficacy of two doses of anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) messenger RNA (mRNA) vaccines, successfully demonstrated in healthy populations,1 is progressively reported in recipients of allogeneic haematopoietic stem cell transplant (allo-HSCT) with, surprisingly, high humoral antibody responses of ~80%.1-3 In our own experience based on an observational study of 117 allo-HSCT adult recipients, we found that 83% of them achieved a significant specific humoral response after two doses (V1 and V2) of BNT162b2 anti-SARS-CoV-2 mRNA vaccine (Pfizer BioNTech). [Extracted from the article]

All except two patients were in complete remission at the time of first vaccine, while three patients were still on therapy (revlimid I n i = 1, tafasitamab I n i = 1, chemotherapy I n i = 1). Keywords: COVID 19; vaccine; CAR-T cells; BNT162b2; SARS-CoV-2 mRNA EN COVID 19 vaccine CAR-T cells BNT162b2 SARS-CoV-2 mRNA 360 362 3 01/17/22 20220115 NES 220115 The efficacy of anti-SARS-CoV-2 messenger RNA vaccines was first demonstrated in healthy populations.1 It was later progressively reported in immunocompromised hosts, including patients with solid tumours,2 haematological malignancies, especially B-cell chronic lymphocytic leukaemia,3,4 as well as solid organ transplants.5,6 Surprisingly, the antibody response has been shown to be impressive (around 80%) only in recipients of allogeneic haematopoietic stem cells transplant.7-9 Another immunocompromised population is patients who have received chimeric antigen receptor-T (CAR T) cell therapy. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. [Extracted from the article]